Inhaled therapeutics company Breath Therapeutics reported on Monday the launch of the Phase 3 BOSTON clinical studies of L-CsA-i in patients with Bronchiolitis Obliterans Syndrome (BOS), a devastating lung disease with high mortality following lung or allogeneic hematopoietic stem cell transplantation.
Symptoms and signs such as tachypnea, tachycardia, loss of appetite and fatigue, which are among the clinical findings of heart failure, can be seen in many patients diagnosed with bronchiolitis. Differential diagnosis of heart failure may become more difficult in patients with accompanied pneumonia who manifest rales in pulmonary auscultation.
Gabrielle Freire, M.D., from the University of Toronto, and colleagues conducted a retrospective cohort study of previously healthy infants aged <12 months with bronchiolitis to identify predictors of escalated care.
Introduction: Acute bronchiolitis, is a predominantly a viral disease, part of the spectrum of lower respiratory tract diseases, is a major cause of illness and hospitalization in infants and children younger than two years.